Thierry Soussi

Q: What Schools Are Affiliated With Thierry Soussi

Thierry Soussi is affiliated with the following schools: Uppsala University, Université Paris Cité, Stanford University, Karolinska Institute, Sorbonne University

Thierry Soussi's AcademicInfluence.com Rankings

Thierry Soussi

Computer Science

#6365

World Rank

#6713

Historical Rank

Computational Linguistics

#1081

World Rank

#1095

Historical Rank

Machine Learning

#2043

World Rank

#2069

Historical Rank

Artificial Intelligence

#2300

World Rank

#2339

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Thierry Soussi's Degrees

PhD Computer Science Université Paris Cité
Masters Artificial Intelligence Stanford University
Bachelors Computer Science Université Paris Cité

Similar Degrees You Can Earn

Why Is Thierry Soussi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thierry Soussi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Database of p53 gene somatic mutations in human tumors and cell lines. (1994) (946)
Assessing TP53 status in human tumours to evaluate clinical outcome (2001) (721)
Structural aspects of the p53 protein in relation to gene evolution. (1990) (637)
TP53 tumor suppressor gene: A model for investigating human mutagenesis (1992) (600)
p53 Antibodies in the sera of patients with various types of cancer: a review. (2000) (577)
Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation (1996) (541)
APC gene: database of germline and somatic mutations in human tumors and cell lines (1996) (462)
Multifactorial analysis of p53 alteration in human cancer: A review (1994) (394)
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. (2005) (387)
Shaping genetic alterations in human cancer: the p53 mutation paradigm. (2007) (370)
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation (2000) (322)
Serum p53 antibodies as early markers of lung cancer (1995) (316)
Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects (1997) (315)
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade (2014) (301)
p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis (2000) (299)
p53 mutation heterogeneity in cancer. (2005) (288)
The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. (1992) (286)
Structural aspects of the p53 protein in relation to gene evolution: a second look. (1996) (283)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. (2019) (273)
Mutant p53 protein localized in the cytoplasm inhibits autophagy (2008) (265)
p53 alterations in human cancer: more questions than answers (2007) (252)
Lymphomas in Patients With Sjögren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses (1997) (241)
Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. (1994) (240)
TP53: an oncogene in disguise (2015) (226)
UMD (Universal Mutation Database): A generic software to build and analyze locus‐specific databases (2000) (216)
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. (2000) (214)
P53 Gene Mutation: Software and Database (1996) (188)
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. (1993) (183)
Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein (1997) (167)
Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. (1987) (167)
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment (2014) (166)
The UMD‐p53 database: New mutations and analysis tools (2003) (164)
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations (2010) (158)
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience (2006) (154)
Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. (1994) (150)
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis (2012) (149)
Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations (2005) (146)
Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. (2002) (146)
Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer (1995) (144)
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma (2010) (137)
Cancer and the heat shock response. (1994) (133)
Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. (1997) (133)
The UMD TP53 database and website: update and revisions (2006) (130)
Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint (1999) (129)
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation (2018) (127)
The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. (1996) (119)
Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides (2003) (117)
UMD (Universal Mutation Database): 2005 update (2005) (112)
Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. (1985) (108)
Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer (1995) (107)
Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. (1988) (106)
Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? (1994) (106)
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. (2006) (104)
Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. (1996) (104)
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination (2008) (104)
Regulation of Mutant p53 Temperature-sensitive DNA Binding* (1996) (100)
p53 mutation as a genetic trait of typical medullary breast carcinoma. (1999) (94)
p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue (1995) (89)
Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. (1997) (89)
Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection (2006) (87)
Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q (1994) (87)
Database and software for the analysis of mutations in the human p53 gene. (1994) (84)
Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors (2012) (83)
Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. (1994) (80)
Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. (1998) (78)
p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. (1995) (78)
Translocation of a store of maternal cytoplasmic c-myc protein into nuclei during early development (1989) (75)
TP53 mutations in human cancer: database reassessment and prospects for the next decade. (2011) (75)
Rainbow trout p53: cDNA cloning and biochemical characterization. (1992) (75)
The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. (2002) (72)
The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. (1996) (70)
Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients (2000) (69)
Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents (1998) (66)
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. (2017) (64)
P53 gene alterations in human tumors: perspectives for cancer control. (1997) (61)
Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. (1998) (60)
Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. (1994) (59)
Software and database for the analysis of mutations in the human FBN1 gene (1996) (59)
p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity (1998) (59)
Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. (2019) (57)
Splice mutations in the p53 gene: case report and review of the literature (2003) (56)
ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter (1996) (55)
The history of p53 (2010) (51)
p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. (1995) (51)
Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. (1995) (50)
The p53 pathway and human cancer (2005) (49)
Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction (2004) (49)
Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73* (2003) (45)
Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network (2019) (44)
An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue (2002) (44)
p53 mutations in BRCA1-associated familial breast cancer (1998) (44)
Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein. (1988) (44)
Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70 (1989) (43)
p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. (1994) (42)
Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer (2000) (42)
Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses (1996) (40)
Stabilization and expression of high levels of p53 during early development in Xenopus laevis. (1993) (39)
Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors (2007) (38)
Breast-cancer stromal cells with TP53 mutations. (2008) (38)
ThinPrep®‐processed fine‐needle samples of breast are effective material for RNA‐ and DNA‐based molecular diagnosis (2003) (37)
Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. (1993) (37)
Characterization of a bovine acidic FGF cDNA clone and its expression in brain and retina (1988) (36)
Serum p53 antibodies: predictors of survival in small-cell lung cancer? (2000) (34)
DNA-binding properties of the major structural protein of simian virus 40 (1986) (33)
Recommendations for Analyzing and Reporting TP53 Gene Variants in the High‐Throughput Sequencing Era (2014) (32)
Serum p53 antibodies in correlation to other biological parameters of breast cancer. (2003) (32)
Erratum: Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas (Cell Reports (2019) 28(5) (1370–1384.e5), (S221112471930885X), (10.1016/j.celrep.2019.07.001)) (2019) (32)
Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. (2003) (30)
MUT‐TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer a (2010) (30)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide (2017) (29)
p53 mutations and resistance to chemotherapy: A stab in the back for p73. (2003) (29)
Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array (2004) (28)
A functional analysis of p53 during early development of xenopus laevis (1997) (28)
Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate. (2019) (26)
The UMD-p 53 Database : New Mutations and Analysis Tools (2003) (26)
Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? (2004) (26)
Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. (1996) (24)
Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors (2004) (23)
Focus on the p53 gene and cancer: Advances in TP53 mutation research (2003) (23)
Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant (1999) (23)
Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved. (1995) (23)
Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. (2011) (23)
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes (2016) (22)
Detection of p73 antibodies in patients with various types of cancer: immunological characterization (2001) (22)
The TP 53 website : an integrative resource centre for the TP 53 mutation database and TP 53 mutant analysis (2012) (22)
Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein (1998) (22)
The cDNA cloning and immunological characterization of hamster p53. (1992) (22)
Quantitative fish determination of chromosome 3 arm imbalances in lung tumors by automated image cytometry. (2004) (20)
p53 and APC gene mutations: software and databases (1997) (20)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. (2019) (20)
Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next‐generation sequencing (2018) (20)
The TP53 Gene Network in a Postgenomic Era (2014) (19)
High prevalence of cancer‐associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering (2019) (19)
Stimulation of rat liver α‐ and β‐type DNA polymerases by an homologous DNA‐unwinding protein (1977) (18)
Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome. (1999) (17)
3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation. (1994) (17)
Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations (2018) (17)
Lack of HIN-1 Methylation Defines Specific Breast Tumor Subtypes Including Medullary Carcinoma of the Breast and BRCA1-Linked Tumors (2003) (17)
P53 Gene Mutation: Software and Database (1998) (17)
Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. (2001) (17)
Locus‐Specific Databases in Cancer: What Future in a Post‐Genomic Era? The TP53 LSDB paradigm (2014) (17)
Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux (2019) (16)
Analysis of p53 Gene Alterations in Cancer: A Critical View (2007) (16)
Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications (2017) (16)
Absence of p53 germ-line mutations in bilateral breast cancer patients (1992) (16)
Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and both the lacI and lacZ gene in transgenic rodents (1997) (16)
Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line (2001) (15)
Medullary breast carcinoma: prognostic implications of p53 expression. (2003) (15)
Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. (1994) (15)
Investigation and prediction of the severity of p53 mutants using parameters from structural calculations (2009) (15)
[Bcl2-associated X protein]. (2001) (14)
Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway (2003) (14)
The Immune Response to p 53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot 1 (1992) (13)
Database and software for the analysis of mutations at the human p53 gene. (1994) (12)
ERIC recommendations for TP 53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results (2018) (12)
p53 gene alterations in human hematological malignancies: a review. (1991) (12)
Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interactions with the mdm2 protein. (2000) (12)
APC gene: database of germline and somatic mutations in human tumors and cell lines (1998) (11)
Functional characterization of Xenopus laevis p53: evidence of temperature-sensitive transactivation but not of repression (1994) (11)
Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene (2020) (11)
Genetic profiling of CLL: a ‘TP53 addict' perspective (2016) (10)
Fam83F induces p53 stabilisation and promotes its activity (2019) (10)
Reassessment of the p 53 mutation database in human disease by data mining with a library of p 53 missense mutations (2004) (9)
Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents (1996) (9)
MUT‐TP53: a versatile matrix for TP53 mutation verification and publication (2006) (8)
Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: a review. (1993) (8)
Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort (2020) (7)
Functional analyses of a unique p53 germline mutant (y236Δ) associated with a familial brain tumor syndrome (1999) (7)
[p53 mutations and resistance to chemotherapy: a stab in the back for p73?]. (2003) (7)
Splice Mutations in the p 53 Gene : Case Report and Review of the Literature (2002) (7)
Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries (2020) (7)
A monoclonal antibody against DNA binding helix of p53 protein (2001) (6)
Monoclonal antibodies raised against Xenopus p53 interact with human p73 (2002) (6)
MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival. (2018) (6)
Very low incidence of p53 antibodies in adult non‐Hodgkin's lymphoma and multiple myeloma (1998) (6)
Analysis of p 53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p 53 : Distribution on Primary Structure and Exposure on Protein Surface 1 (2006) (6)
Le dosage sérique des anticorps anti-p53: application au cancer colorectal (2000) (5)
Genes and mechanisms involved in early embryonic development in Xenopus laevis. (1990) (4)
Detection and monitoring of serum p 53 antibodies in patients with colorectal cancer (4)
When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy? (2009) (3)
[P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer]. (1996) (3)
The role of p53 in normal cells and in cancer development. (1997) (3)
[P53 tumor suppressor gene]. (1993) (3)
TP53 and 53BP1 Reunited. (2017) (3)
[The p53 gene and protein in bronchial carcinogenesis:from biological to clinical aspects]. (1994) (3)
Colorectal cancer is associated with the presence of cancer driver mutations in normal colon (2021) (3)
[Serum p53 antibody assay: evaluation in colorectal cancer]. (2000) (3)
Medullary Breast Carcinoma: Prognostic Implications of P53 Expression (2003) (2)
Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog (2022) (2)
[Tumor suppressor p53 gene: a potential target for cancer therapy?]. (1997) (2)
Le gène suppresseur de tumeur p53 (1997) (2)
[Role of the p53 gene in human malignant tumors. A major discovery in oncology]. (1993) (2)
[Genetic alterations in localized cancers of the prostate: identification of a common region of deletion on the chromosome 18q]. (1995) (2)
Benign single-nucleotide polymorphisms in the coding region of TP53: finding the needles in a haystack of pathogenic variants. (2022) (1)
Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. (2022) (1)
A new set of monoclonal antibodies directed to proline-rich and central regions of p53. (2004) (1)
[Genes and cancer. NBS1 (Nijmegen breakage syndrome). Repair gene]. (1999) (1)
Chapter 12 ANALISYS OF P 53 GENE AALTERATIONS IN CANCER : A CRITICAL VIEW (2005) (1)
Ultra-sensitive sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan (2018) (1)
Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases (2022) (1)
Multifactorial analyasis of P53 alterations in human cancer (1993) (1)
Author Correction: Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux (2019) (1)
Prevalence, distribution and predictive value of XPO1 mutation in a real‐life chronic lymphocytic leukaemia cohort (2020) (1)
Human double minute 2 (MDM2 in the mouse) - Oncoprotein (2000) (1)
[Genes & cancer. Card no. 28: PTEN (MMAC, TEP-1) (phosphatase and tensin homolog deleted on chromosome 10)]. (1999) (1)
[Record no. 23: hMLH1]. (1999) (1)
[Li-Fraumeni syndrome and germ-line mutations of the p53 gene]. (1994) (1)
Erratum to Morselli E, et al. Cell Cycle 2008; 7:3056–61 (2014) (1)
[p53 and Rb, clinical and therapeutic perspectives]. (1993) (0)
[Record no. 22: Beta-catenin]. (1999) (0)
SMAD4/DPC4 (small mothers against decapentaplegic deleted in pancreatic carcinoma, locus 4): Gène suppresseur de tumeur (1998) (0)
Gène Ret (REarranged during transfection) (1998) (0)
The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis (1998) (0)
[Chart no 45 - WRN (RCQL3)]. (2001) (0)
[INK4a-ARF (MTS1) or inhibitor of CDK-alternating reading frame (multiple tumor suppressor gene)]. (1999) (0)
hCDC4 (FBW7, AGO, Archipelago) (2006) (0)
The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants (2019) (0)
Gène anti-apoptotique : Bcl2 (B cell lymphoma) (1998) (0)
Fumarate hydratase (fumarase, FH, EC4.2.1.2) (2006) (0)
Detection andmonitoring ofserump53antibodies inpatients withcolorectal cancer (2011) (0)
[Perspectives of practical application for studies of gene p53]. (1994) (0)
Surface plasmon resonance based imaging system and some of its multiple biosensing applications (2003) (0)
[Fli-1 (Friend leukemia integration 1). Oncogene]. (1998) (0)
[File no. 40. DNA polymerase n (Pol H) in hRad30A. Repair gene]. (2000) (0)
P53 (protein 53 kDa) (2011) (0)
Atlas of Genetics and Cytogenetics in Oncology and Haematology (2003) (0)
MET (c-met, hepatocyte growth factor receptor) (2005) (0)
Oncogène : TAL1 (SCL) (T cell leukemia 1) (1998) (0)
[File no. 41. VHL (von Hippel-Lindau). Tumor suppressor gene]. (2000) (0)
[BLM (RCQL2) or Bloom Syndrome]. (2001) (0)
Correlations between p53 overexpression, serum antibodies and gene mutation in colorectal cancer (1998) (0)
Gene p 53 Human Database and Software for the Analysis of Mutations in the Updated (2006) (0)
Gène PML (Promyelocytic Leukemia) (1999) (0)
A monoclonal antibody against DNA binding helix of p 53 protein (2001) (0)
p53 diagnosis in human cancer: what utility? (2001) (0)
FLT3 (Stem cell tyrosine kinase 1, STK1, CD135 antigen) (2005) (0)
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53 (2022) (0)
[44 .PMS2 (post meiotic segregation increased, S. cerevisiae 2]. (2001) (0)
Fiche n°34 : Gène : hSNF5/INI1 (SMARCB1) ou sucrose non fermenting/integrase interactor SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1 - Catégorie : Gène suppresseur de tumeur (2000) (0)
[Case No. 36: E-cadherin (uvomorulin or CDH1]. (2000) (0)
[File no.47: CMYC]. (2001) (0)
EGFR (epidermal growth factor receptor), V-ERB-B, ERBB1 oncogène (2005) (0)
[PML (promyelocytic leukemia). Oncogene]. (1999) (0)
FINE EPITOPIC SPECIFICITY AND AFFINITY OF VARIOUS p53 MONOCLONAL ANTIBODIES (1996) (0)
765 Multifactorial analysis of p53 alteration in human cancer (1995) (0)
p53 overexpression in node-negative breast cancer: Prognostic significance in a randomized study? (1997) (0)
Methylcholanthrene Inactivates the p 53 Gene in Syrian Hamster Embryo Fibroblasts by Inducing a Specific Intronic Point Mutation 1 (2006) (0)
[Genetics and cancer: fundamental and clinical aspects]. (2001) (0)
Rb1 (rétinoblastome): Gène suppresseur de tumeur (1998) (0)
Stimulation of rat liver alpha- and beta-type DNA polymerases by an homologous DNA-unwinding protein. (1977) (0)
[Chart 48: FANCG/XRCC9 (type G Fanconi's anemia)]. (2001) (0)
Abstract 2735: Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs) (2016) (0)
Gène RASSF1 (ras association domain family protein 1) (2005) (0)
[Chart no. 30: FANCA (Fanconi's anemia type A). Repair gene?]. (1999) (0)
TP53 (Tumour protein p53 (Li-Fraumeni syndrome)) (2018) (0)
[Record no. 34: hSNF5/INI1 (SMARCB1)]. (2000) (0)
[PTPC (Patched). Tumor suppressor gene]. (1999) (0)
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia (2022) (0)
Fiche no. 32: ATM (ataxie telangiectasie mutated). (2000) (0)
[Genes and cancers: c-Kit, SCFR (stem cell factor receptor) CD117]. (2001) (0)
399 P53 serum antibodies in head and neck SCC (1995) (0)
Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux (2019) (0)
Gène suppresseur de tumeur (2005) (0)
Fiche no. 27: INK4a-ARF (MTS1) or inhibitor of CDK-alternative reading frame (multiple tumor suppressor gene). (1999) (0)
[Immunochemistry and genotype analysis of tumors. Second part: What future for the molecular diagnosis of tumors?]. (2002) (0)
[Record no. 39: p53 (TP53)]. (2000) (0)
[Case No. 37: hdm2 (mdm2 in mice)]. (2000) (0)
BRCA1 (breast cancer type 1): Gène suppresseur de tumeur (1998) (0)
[Record no. 38: TGFBR2 (type II TGFbeta receptor)]. (2000) (0)
Fam83F induces p53 stabilisation and promotes its activity (2019) (0)
[Card no. 32: ATM (Ataxia Telangiectasia Mutated)]. (2000) (0)
Dorian Gray mice exposed (1993) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thierry Soussi?

Thierry Soussi is affiliated with the following schools:

Thierry Soussi's Academic­Influence.com Rankings

Thierry Soussi's Degrees

Similar Degrees You Can Earn

Why Is Thierry Soussi Influential?

Thierry Soussi's Published Works

Published Works

What Schools Are Affiliated With Thierry Soussi?

Thierry Soussi's AcademicInfluence.com Rankings